Selexis SA today announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs utilizing...
Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing ...
Paper in Frontiers in Immunology Describes Trimer Design and Development of Production CHO Cell Lines That Generate Properly Folded HIV-1 Env Trimers to Support Goal of Developing an Effective HIV ...
The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.
JSR will be providing the equity capital for OPM Asia that will enable the establishment of a world-class biomedical manufacturing and market development operation.
2 of 4
Receive JSR Life Sciences news on your RSS reader.
